Feasibility of Isolating P16 Expression
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/3/2019 |
| Start Date: | May 25, 2017 |
| End Date: | June 1, 2019 |
| Contact: | Kirsten K. Ness, PT, PhD |
| Email: | referralinfo@stjude.org |
| Phone: | 866-278-5833 |
Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In
mice, both radiation and chemotherapy are known to increase p16. Due to its influence on
age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic
reserve that may identify patients able to withstand the stressor of chemotherapy (low p16)
from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may
predict physiologic, rather than chronologic, age. Such findings could have implications for
care of cancer survivors and treatment decision-making in cancer patients.
STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of
isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer
during childhood.
mice, both radiation and chemotherapy are known to increase p16. Due to its influence on
age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic
reserve that may identify patients able to withstand the stressor of chemotherapy (low p16)
from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may
predict physiologic, rather than chronologic, age. Such findings could have implications for
care of cancer survivors and treatment decision-making in cancer patients.
STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of
isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer
during childhood.
At St. Jude Children's Research Hospital, survivors who meet the eligibility criteria will be
identified from SJLIFE protocol participants. After signing consent, the subject will have a
blood specimen collected at the same time as the blood draw for the SJLIFE protocol. These
samples will have T cell isolation performed then placed on ice and stored until batch
shipment for investigation of p16 expression.
identified from SJLIFE protocol participants. After signing consent, the subject will have a
blood specimen collected at the same time as the blood draw for the SJLIFE protocol. These
samples will have T cell isolation performed then placed on ice and stored until batch
shipment for investigation of p16 expression.
Inclusion Criteria:
- Enrolled in the SJLIFE study at St. Jude children's Research Hospital.
- Survivor of childhood cancer.
- Is 18 years of age and older.
- No evidence of cancer recurrence.
- Received prior chemotherapy (prior radiotherapy is allowed).
Exclusion Criteria:
- Inability or refusal to give consent.
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Kirsten Ness, PT, PhD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
